妇科肿瘤标志物的临床应用。

Clinical use of gynaecologic tumour markers.

作者信息

Halila H, Alfthan H, Stenman U H

机构信息

First Department of Obstetrics and Gynaecology, Helsinki University Central Hospital, Finland.

出版信息

Ann Chir Gynaecol. 1989;78(1):65-70.

PMID:2547331

Abstract

Tumour markers have proved to be important in certain types of gynaecological cancer. The treatment of chorionic cancer is largely based on changes in the serum levels of human choriogonadotropin (hCG). There are no other markers of equal utility, but some new markers for ovarian cancer show promise of becoming clinically important in the follow-up of patients. Assay of CA 125 has become a routine method in the follow-up of nonmucinous ovarian cancer, and tumour-associated trypsin inhibitor (TATI) shows promise of being useful for mucinous ovarian cancer. In the rare ovarian embryonal tumours hCG and alphafetoprotein (AFP) are often useful. For other types of gynaecological cancer, there are no equally useful markers, but CA 125 is relatively useful in endometrial cancer and SCC (squamous cell carcinoma-associated antigen) in cervical cancer. Carcinoembryonic antigen (CEA) is occasionally useful in ovarian and cervical cancer.

摘要

肿瘤标志物已被证明在某些类型的妇科癌症中很重要。绒毛膜癌的治疗很大程度上基于血清人绒毛膜促性腺激素（hCG）水平的变化。没有其他具有同等效用的标志物，但一些卵巢癌的新标志物有望在患者随访中变得具有临床重要性。CA 125检测已成为非黏液性卵巢癌随访的常规方法，肿瘤相关胰蛋白酶抑制剂（TATI）有望用于黏液性卵巢癌。在罕见的卵巢胚胎性肿瘤中，hCG和甲胎蛋白（AFP）通常很有用。对于其他类型的妇科癌症，没有同样有用的标志物，但CA 125在子宫内膜癌中相对有用，而鳞状细胞癌相关抗原（SCC）在宫颈癌中相对有用。癌胚抗原（CEA）偶尔在卵巢癌和宫颈癌中有用。